BioCentury | Mar 23, 2018
Clinical News

Inovio reports interim Phase I data for HBV candidate

...Pharmaceuticals Inc. (NASDAQ:INO) reported interim data from a Phase I trial showing that HBV candidate INO-1800...
...cells. The open-label, dose-escalation, international trial enrolled 90 patients with chronic HBV infection to receive INO-1800...
...HBsAg) kinetics and HBV DNA suppression. Inovio Pharmaceuticals Inc. (NASDAQ:INO), Plymouth Meeting, Pa. Product: SynCon DNA HBV vaccine (INO-1800...
BioCentury | Aug 8, 2016
Company News

Inovio, Roche deal

...Inovio said Roche is terminating a 2013 deal and returning exclusive, worldwide rights to Inovio’s INO-1800...
...a “strategic decision” and that the pharma will pay Inovio R&D costs per the agreement. INO-1800...
BioCentury | Aug 3, 2016
Company News

Roche returning rights to Inovio's HBV vaccine

...terminating a 2013 deal and is returning exclusive, worldwide rights to Inovio's hepatitis B vaccine INO-1800...
...genotype A through E of the hepatitis B core antigen (HBcAg). The study is evaluating INO-1800...
BioCentury | May 25, 2015
Clinical News

SynCon DNA HBV vaccine: Phase I started

...Inovio began an open-label, dose-escalation, international Phase I trial evaluating INO-1800 alone or in combination with...
...to Inovio from Roche under a 2013 deal granting the pharma exclusive, worldwide rights to INO-1800...
...Inovio Pharmaceuticals Inc. (NASDAQ:INO), Blue Bell, Pa. Roche (SIX:ROG; OTCQX:RHHBY), Basel, Switzerland Product: SynCon DNA HBV vaccine ( INO-1800...
BioCentury | Sep 16, 2013
Company News

Inovio, Roche deal

...Inovio granted Roche exclusive, worldwide rights to prostate cancer vaccine INO-5150 and hepatitis B vaccine INO-1800...
...PSMA ; FOLH1 ; GCPII ) synthetic consensus immunogens based on human and monkey sequences. INO-1800...
...for INO-5150 and INO-1800, both of which are in preclinical testing. Inovio re-acquired rights to INO-1800...
BioCentury | Sep 11, 2013
Company News

Inovio licenses preclinical immunotherapy vaccines to Roche

...Roche (SIX:ROG; OTCQX:RHHBY) exclusive, worldwide rights to prostate cancer vaccine INO-5150 and hepatitis B vaccine INO-1800...
...PSMA ; FOLH1 ; GCPII ) synthetic consensus immunogens based on human and monkey sequences. INO-1800...
...Inovio is eligible for additional undisclosed milestones if Roche pursues other indications for INO-5150 and INO-1800...
BioCentury | Dec 17, 2012
Clinical News

Inovio preclinical data

...In mice, Inovio's SynCon DNA HBV vaccine delivered with the company's electroporation system induced "strong" antigen-specific T cell and...
...HCV infection (see BioCentury, Oct. 17, 2011). Inovio Pharmaceuticals Inc. (NYSE-M:INO), Blue Bell, Pa. Product: SynCon DNA HBV vaccine...
Items per page:
1 - 7 of 7